Abcam acquires Calico Biolabs

Calico develops custom recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies

Abcam has acquired Calico Biolabs, a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies.

Headquartered in Cambridge, UK, Abcam is a global supplier of research tools for the life sciences industry.

The transaction expands Abcam’s position in rabbit monoclonal antibodies, bringing a small catalogue of ready-made CAL antibodies for immunohistochemistry (IHC) in addition to custom development services.

John Baker, SVP of Product Portfolio and Innovation at Abcam, commented: "The acquisition of Calico represents execution of our strategy to provide the best and highest quality products to our diagnostic, biopharmaceutical and research customers.

"By incorporating Calico’s product portfolio and custom services, Abcam expands its offering of rabbit monoclonals for IHC, allowing development of more products for their most important targets, faster. We are excited to welcome the Calico team to the Abcam family, furthering Abcam’s mission to provide customers with the highest quality recombinant antibodies for their research.”

Calico’s range of ready-made recombinant CAL antibodies for critical immuno-oncology targets will be made available at both research and commercial scale via the Abcam global commercial network.

Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings for FY2019.

Jacinto Villanueva, CEO of Calico, commented: “This move will enable us to more fully support the cancer research and associated diagnostics development being carried out by our industry partners.”

Calico Biolabs is headquartered in Pleasanton, California. The company partners with diagnostic and pharmaceutical companies, both large and small, to develop custom rabbit monoclonal antibodies.

Companies